Business Wire

GE, Roche Enter Partnership to Develop Integrated Digital Diagnostics Platform to Improve Oncology and Critical Care Treatment

Jaa

GE Healthcare has entered into a strategic, long-term partnership with Roche (SIX: RO, ROG; OTCQX: RHHBY) to jointly develop and co-market digital clinical decision support solutions. The partnership will initially focus on products that accelerate and improve individualized treatment options for cancer and critical care patients.

This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20180107005109/en/

GE, Roche Enter Partnership to develop an industry-first digital platform, using advanced analytics  ...

GE, Roche Enter Partnership to develop an industry-first digital platform, using advanced analytics to provide workflow solutions and apps that support clinical decisions (Photo: Business Wire)

The two companies aim to develop an industry-first digital platform, using advanced analytics to provide workflow solutions and apps that support clinical decisions. This will allow the seamless integration and analysis of in-vivo and in-vitro data, patient records, medical best practice, real time monitoring and the latest research outcomes. Clinicians will then have the comprehensive decision support for providing the right treatment and quality of care for their patients.

For example, oncology care teams with multiple specialists will have a comprehensive data dashboard to review, collaborate and align on treatment decisions for cancer patients at each stage of their disease. In the critical care setting, data from a patient’s hospital monitoring equipment will be integrated with their biomarker, tissue pathology, genomic and sequencing data, helping physicians to identify, or even predict severe complications before they strike.

GE Healthcare is a worldwide leader in medical imaging equipment, while Roche Diagnostics is the global leader in in-vitro diagnostics.

“This is the first time that two major players in healthcare have combined advanced analytics with in-vivo and in-vitro diagnostics to this degree. We believe this alliance will help accelerate the delivery of data-driven precision health for customers, patients and the healthcare industry,” said Kieran Murphy, President & CEO of GE Healthcare.

“This unique partnership will deliver innovative solutions and insights in clinical decision-making. Our goal is to support clinicians and other relevant stakeholders for the benefit of patients by providing the right decision support at the right time and through comprehensive digital offerings,” said Roland Diggelmann, CEO Roche Diagnostics.

About GE Healthcare:

Harnessing data and analytics across hardware, software and biotech, GE Healthcare is the $18 billion healthcare business of GE (NYSE: GE). As a leading provider of medical imaging equipment, with a track record of more than 100 years in the industry and more than 50,000 employees across 100 countries, we transform healthcare by delivering better outcomes for providers and patients. Visit us at www.gehealthcare.com or follow us on Facebook, LinkedIn, Twitter and The Pulse for latest news

About Roche

Roche is a global pioneer in pharmaceuticals and diagnostics focused on advancing science to improve people’s lives. The combined strengths of pharmaceuticals and diagnostics under one roof have made Roche the leader in personalised healthcare – a strategy that aims to fit the right treatment to each patient in the best way possible.

The Roche Group, headquartered in Basel, Switzerland, is active in over 100 countries and in 2016 employed more than 94,000 people worldwide. In 2016, Roche invested CHF 9.9 billion in R&D and posted sales of CHF 50.6 billion. Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan. For more information, please visit www.roche.com.

Contact information

GE Healthcare
William Spiers +44 7971276757
william.spiers@ge.com
or
Jennifer Fox +1 +1 414 530 3027
jennifer.r.fox@ge.com
or
Hannah Huntly +44 7887 824201
hannah.huntly@ge.com
or
Roche Group Media Relations
Phone: +41 -61 688 8888 / e-mail: media.relations@roche-global.com
- Nicolas Dunant (Head)
- Patrick Barth
- Ulrike Engels-Lange
- Simone Oeschger
- Anja von Treskow

Tietoja julkaisijasta

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Tilaa tiedotteet sähköpostiisi

Haluatko tietää asioista jo ennen kuin ne uutisoidaan? Kun tilaat tiedotteemme, saat ne sähköpostiisi yhtä aikaa suomalaisen median kanssa. Tilauksen voit halutessasi perua milloin tahansa.

Lue lisää julkaisijalta Business Wire

Westinghouse AP1000® Plant to Load Fuel25.4.2018 15:14Tiedote

Westinghouse Electric Company, China State Nuclear Power Technology Corporation (SNPTC) and CNNC Sanmen Nuclear Power Company Limited (SMNPC) announced today that the world’s first unit of AP1000 nuclear power plant located in Sanmen, Zhejiang Province, China, has received the fuel load permit from China’s National Nuclear Safety Administration (NNSA) and has commenced initial fuel loading. “Today we have reached a tremendous milestone for Westinghouse and our AP1000 plant technology,” said José Emeterio Gutiérrez, Westinghouse president and chief executive officer. “This is the next major step in delivering the world’s first AP1000 plant to our customer and demonstrating the benefits of our advanced passive safety technology to the world.” Sanmen Unit 1 has successfully completed all the necessary functional tests as well as technical, safety and Chinese regulatory reviews. The fuel load process will be followed by initial criticality, initial synchronization to the electrical grid, a

Elliott Advisors (UK) Limited Statement on Whitbread25.4.2018 15:03Tiedote

Elliott Advisors (UK) Limited (“Elliott”) is pleased that Whitbread has announced a demerger and has committed to doing so “as fast as practical”. In Elliott’s view this should be achieved within six months. About Elliott Elliott Management Corporation manages two multi-strategy funds which combined have approximately $35 billion of assets under management. Its flagship fund, Elliott Associates, L.P., was founded in 1977, making it one of the oldest funds of its kind under continuous management. The Elliott funds’ investors include pension plans, sovereign wealth funds, endowments, foundations, funds-of-funds, and employees of the firm. Elliott Advisors (UK) Limited is an affiliate of Elliott Management Corporation. View source version on businesswire.com: https://www.businesswire.com/news/home/20180425005814/en/ Contact information Media Contacts Elliott Advisors (UK) Limited Sarah Rajani CFA Director of Communications Elliott Advisors (UK) Limited +44 (0) 20 3009 1818 srajani@elliott

Incognito Launches Digital Home Experience Solution25.4.2018 15:00Tiedote

Incognito Software Systems, a global provider of device and service management solutions for digital service providers, today introduced the Digital Home Experience Solution. The new offering enhances the existing Incognito Auto Configuration Server with improved digital channels, and analytics to address service quality challenges associated with complex, multi-device home WiFi networks. In production with a Tier 1 service provider, the solution is accelerating technical problem resolution, reducing operational costs with fewer truck rolls, while improving customer satisfaction. “Digital transformation in the home network is accelerating, as service providers look to eliminate friction points such as how to automate the resolution of service quality issues,” said Anil Rao, Principal Analyst, Analysys Mason. “It is in this context that Incognito’s new Digital Home Experience Solution is relevant. Communication service providers are investing in such solutions to boost customer satisfac

Boehringer Ingelheim R&D Pushes to Transcend Disease Boundaries25.4.2018 14:30Tiedote

Family-owned pharmaceutical company Boehringer Ingelheim today presented its latest pipeline updates at a Research & Development press conference entitled ‘Transcending Disease Boundaries’, at its global headquarters in Ingelheim, Germany. The company’s R&D strategy and current pipeline has the potential to deliver 15 new medicines for approval by 2025 (probability adjusted). With a high percentage of first-in-class and breakthrough potential drug candidates, Boehringer Ingelheim continues the successful implementation of its R&D strategy. Boehringer Ingelheim is committing more than €20 billion to Research & Development for human pharmaceuticals by 2025. In the past four years, the company received 14 regulatory approvals in several new indications, including four new molecular entities and four breakthrough designations by the US Food and Drug Administration. “The most ambitious goal for researchers is to achieve a medical breakthrough for patients from our over 80 clinical and pre-c

Corvidia Therapeutics Secures $60 Million in Series B Funding to Accelerate Clinical Work25.4.2018 14:00Tiedote

Corvidia Therapeutics Inc., a leading clinical stage biotechnology company, today announced the close of a $60 million USD Series B funding round. The financing will accelerate growth of Corvidia’s ongoing clinical programs, expand scientific and market access capabilities and explore new treatment areas. Venrock led the Series B financing and was joined by five additional new investors: Andera (formerly Edmond de Rothschild), Cormorant Asset Management, HBM Healthcare Investments, Fresenius Medical Care Ventures GmbH and Venrock Healthcare Capital Partners (VHCP). Series A investors Apple Tree Partners, MedImmune, the global biologics Research and Development arm of AstraZeneca, and Sofinnova Partners, the founding seed investor, also participated in this round. “We are extremely pleased to have reached such an important milestone in Corvidia’s advancement as a biotechnology company,” said Marc de Garidel, Chief Executive Officer of Corvidia Therapeutics Inc. “This funding is critical

LTI Congratulates American Modern Insurance Group, Inc. for Winning the Celent 2018 Model Insurer Award25.4.2018 13:30Tiedote

Larsen & Toubro Infotech Ltd. (NSE: LTI, BSE: 540005), a global technology consulting and digital solutions company, congratulates its client, American Modern Insurance Group, Inc. (American Modern) for winning Celent’s 2018 Model Insurer award. Celent is a global research and advisory firm for the financial services industry. American Modern, located in suburban Cincinnati, Ohio, provides specialty insurance products and services for the residential property and recreational markets. Celent’s annual Model Insurer Awards recognize the best practices of technology usage in areas critical to success in the insurance industry. American Modern is honored with a Celent 2018 Model Insurer award for operational excellence for its automation efforts that resulted in increased productivity and improved customer experience. A detailed case study of each winning initiative, including American Modern, is included in Celent’s annual Model Insurer report. Anil Vazirani, Chief Business Officer, Insur

Uutishuoneessa voit lukea tiedotteitamme ja muuta julkaisemaamme materiaalia. Löydät sieltä niin yhteyshenkilöidemme tiedot kuin vapaasti julkaistavissa olevia kuvia ja videoita. Uutishuoneessa voit nähdä myös sosiaalisen median sisältöjä. Kaikki STT Infossa julkaistu materiaali on vapaasti median käytettävissä.

Tutustu uutishuoneeseemme